Acetic acid (2S,3R,5S)-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-fluoro-tetrahydro-furan-2-yl ester | 170079-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: Acetic acid (2S,3R,5S)-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-fluoro-tetrahydro-furan-2-yl ester
• 英文别名: [(2S,3R,5S)-5-[[tert-butyl(diphenyl)silyl]oxymethyl]-3-fluorooxolan-2-yl] acetate
• CAS: 170079-96-6
• 化学式: C₂₃H₂₉FO₄Si
• 分子量: 416.565
• InChiKey: SNEMZRPTEPGRFO-VLCRHTCISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  29.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  44.76
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  Acetic acid (2S,3R,5S)-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-fluoro-tetrahydro-furan-2-yl ester 在 氟化铵 、 三氟甲磺酸三甲基硅酯 作用下， 以 甲醇 为溶剂， 生成 1-(2,3-dideoxy-2-fluoro-β-D-erythro-pentofuranosyl)thymine
  参考文献：
  名称：

  A Completely Diastereoselective Electrophilic Fluorination of a Chiral, Noncarbohydrate Sugar Ring Precursor:  Application to the Synthesis of Several Novel 2‘-Fluoronucleosides

  摘要：

  A new and completely diastereoselective method for the introduction of fluorine into a noncarbohydrate sugar ring precursor has been developed. The use of N-fluorodibenzenesulfonimide (5) for the electrophilic fluorination of chiral lactone 4, which is derived from L-glutamic acid, yields the key intermediate 6. This is transformed into an anomeric acetate 8 and is used for the synthesis of a number of novel alpha-2'-fluoronucleosides. Since glutamic acid is used as the synthetic starting material, the L enantiomer may also be synthesized simply by using D-glutamic acid. The incorporation of fluorine into the 2' position of the nucleoside provides several advantages including acid stability of the anomeric bond and general resistance to oxidative metabolism. Further, fluorine is a close mimic of hydroxyl groups in size and polarity and in its ability to act as a hydrogen bond acceptor. This may aid in the recognition of these nucleosides by the enzymes involved in nucleoside activation.

  DOI：

  10.1021/jo9717898
• 作为产物：
  描述：

  (S)-(+)-5-氧代-2-四氢呋喃羧酸 在 吡啶 、 4-二甲氨基吡啶 、 dimethyl sulfide borane 、 二异丁基氢化铝 、 lithium hexamethyldisilazane 作用下， 生成 Acetic acid (2S,3R,5S)-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-fluoro-tetrahydro-furan-2-yl ester
  参考文献：
  名称：

  [EN] NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO
  [FR] COMPOSITIONS THÉRAPEUTIQUES RENFERMANT DES NUCLÉOTIDES ET DES NUCLÉOSIDES, COMBINAISONS ET UTILISATIONS ASSOCIÉES

  摘要：

  本披露涉及含有至少一个硫醇、硫醚或硫代硫醇基团的核苷酸和核苷治疗组合物及其在治疗传染病、病毒感染和癌症方面的用途。该核苷酸和核苷治疗组合物可以包括至少一种第二种抗病毒剂，例如治疗或预防肠道病毒感染的抗病毒剂。

  公开号：

  WO2022235874A1

文献信息

• [EN] NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO<br/>[FR] COMPOSITIONS À BASE DE NUCLÉOTIDE ET DE NUCLÉOSIDE ET UTILISATIONS CORRESPONDANTES
  申请人：UNIV EMORY

  公开号：WO2015038596A1

  公开（公告）日：2015-03-19

  This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

  这份披露涉及到核苷酸和核苷类治疗组合物，用于治疗传染病、病毒感染和癌症，在这些组合物中，核苷酸或核苷的碱基至少含有一个硫醇、硫酮或硫醚。
• [EN] NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES RENFERMANT DES NUCLÉOTIDES ET DES NUCLÉOSIDES ET UTILISATIONS ASSOCIÉES
  申请人：UNIV EMORY

  公开号：WO2014124430A1

  公开（公告）日：2014-08-14

  This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to halogenated nucleosides optionally conjugated to a phosphorus oxide or pharmaceutically acceptable salts thereof. In certain embodiments, the disclosure relates to conjugate compounds or pharmaceutically acceptable salts thereof comprising an amino acid ester or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising these compounds for uses in treating infectious diseases, viral infections, and cancer.

  这项披露涉及核苷酸和核苷类治疗组合物及其相关用途。在某些实施例中，该披露涉及卤代核苷，可选择地与磷氧化物或其药用可接受盐结合。在某些实施例中，该披露涉及结合物或其药用可接受盐，包括通过磷氧化物与核苷酸或核苷相连的氨基酸酯或鞘脂类或衍生物。在某些实施例中，该披露考虑了包括这些化合物的药用组合物，用于治疗传染病、病毒感染和癌症。
• 2′-fluoronucleosides
  申请人：Schinazi Raymond F.

  公开号：US09180138B2

  公开（公告）日：2015-11-10

  2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.

  披露了用于治疗乙型肝炎感染、丙型肝炎感染、艾滋病毒和异常细胞增殖（包括肿瘤和癌症）的2'-氟核苷类化合物。这些化合物具有以下一般化学式： 其中 Base是嘌呤或嘧啶碱基； R1是OH、H、OR3、N3、CN、卤素、CF3、较低的烷基、氨基、较低的烷基氨基、二(较低)烷基氨基或烷氧基； R2是H、磷酸酯或稳定的磷酸酯前药；酰基，或其他药学上可接受的离去基，如苄基、脂质、氨基酸、肽或胆固醇； R3是酰基、烷基、磷酸酯或其他药学上可接受的离去基；或其药学上可接受的盐。